-

INVESTOR ALERT: Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed Against J2 Global, Inc. and Encourages Investors to Contact the Firm Before September 8, 2020

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Central District of California on behalf of those who acquired J2 Global, Inc. (“J2 Global” or the “Company”) (NASDAQ: JCOM) securities during the period from October 5, 2015 through June 29, 2020 (the “Class Period”). Investors have until September 8, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) J2 Global engaged in undisclosed related party transactions; (2) J2 Global used misleading accounting to hide requisite impairments and underperformance in acquisitions; (3) several so-called independent members of the Company's board of directors and audit committee were not disinterested; and (4) as a result, defendants' public statements were materially false and/or misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

If you acquired J2 Global securities during the Class Period, have information, or would like to learn more about these claims, please contact Thomas W. Elrod of Kirby McInerney at 212-371-6600, by email at investigations@kmllp.com, or by filling out this contact form, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, and whistleblower litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney’s website: www.kmllp.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq., (212) 371-6600
investigations@kmllp.com
www.kmllp.com

Kirby McInerney LLP

NASDAQ:JCOM

Release Versions
$Cashtags

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq., (212) 371-6600
investigations@kmllp.com
www.kmllp.com

Social Media Profiles
More News From Kirby McInerney LLP

UNCY INVESTOR REMINDER: Unicycive Therapeutics, Inc. Investors Have Until November 2, 2026 To Contact Kirby McInerney LLP to Seek Lead Plaintiff Role

NEW YORK--(BUSINESS WIRE)--If you have suffered a loss on your Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost.Investors have until November 2, 2026 to ask the Court to appoint them as lead plaintiff. Courts do not consider applications filed after...

YSS INVESTOR REMINDER: York Space Systems Inc. Investors Have Until October 30, 2026 To Contact Kirby McInerney LLP to Seek Lead Plaintiff Role

NEW YORK--(BUSINESS WIRE)--If you have suffered a loss on your York Space Systems Inc. (“York” or the “Company”) (NYSE: YSS) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost. Investors have until October 30, 2026 to ask the Court to appoint them as lead plaintiff. Courts do not consider applications filed after this deadli...

BBNX INVESTOR ALERT: Securities Class Action Filed Against Beta Bionics, Inc. – Investors Encouraged to Contact Kirby McInerney LLP

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) securities during the period of July 30, 2025 through February 24, 2026, inclusive (“the Class Period”). Investors are encouraged to contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or i...
Back to Newsroom